Trial Outcomes & Findings for The Efficacy and Economics of Exercise Maintenance Post-Cardiac Rehabilitation (NCT NCT01658683)
NCT ID: NCT01658683
Last Updated: 2026-08-14
Results Overview
Physical activity will be measured directly by having participants wear the Actigraph GT3X accelerometer (Actigraph, Pensacola, Florida) over the right hip for a 9-day recording period, excluding periods when they are sleeping, swimming, or bathing. The activity monitor provides measurements including activity counts, energy expenditure, and step counts, in addition to activity intensity levels. Participants will be considered to be maintaining exercise at guideline recommended levels if they undertake ≥ 30 minutes of moderate and/or vigorous intensity physical activity on ≥ five days. The results report the average minutes of exercise recorded across the full 9 days wearing the accelerometer.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
449 participants
Primary outcome timeframe
Baseline to 52 weeks
Results posted on
2026-08-14
Participant Flow
Participant milestones
| Measure |
Exercise Facilitator Intervention
The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
|
Usual Care
Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention \& Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
|
|---|---|---|
|
Overall Study
STARTED
|
226
|
223
|
|
Overall Study
COMPLETED
|
146
|
160
|
|
Overall Study
NOT COMPLETED
|
80
|
63
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Participants were identified as white ethnocultural background or other.
Baseline characteristics by cohort
| Measure |
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Total
n=449 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
65.3 years
STANDARD_DEVIATION 10.3 • n=11 Participants
|
66.1 years
STANDARD_DEVIATION 10.5 • n=11 Participants
|
63.0 years
STANDARD_DEVIATION 9.8 • n=22 Participants
|
63.2 years
STANDARD_DEVIATION 9.4 • n=255 Participants
|
63.88 years
STANDARD_DEVIATION 9.92 • n=83 Participants
|
|
Sex: Female, Male
Female
|
68 Participants
n=11 Participants
|
67 Participants
n=11 Participants
|
0 Participants
n=22 Participants
|
0 Participants
n=255 Participants
|
135 Participants
n=83 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=11 Participants
|
0 Participants
n=11 Participants
|
158 Participants
n=22 Participants
|
156 Participants
n=255 Participants
|
314 Participants
n=83 Participants
|
|
Race/Ethnicity, Customized
White ethnocultural background
|
55 Participants
n=11 Participants • Participants were identified as white ethnocultural background or other.
|
56 Participants
n=11 Participants • Participants were identified as white ethnocultural background or other.
|
124 Participants
n=22 Participants • Participants were identified as white ethnocultural background or other.
|
118 Participants
n=255 Participants • Participants were identified as white ethnocultural background or other.
|
353 Participants
n=83 Participants • Participants were identified as white ethnocultural background or other.
|
|
Race/Ethnicity, Customized
Non-white ethnocultural background
|
13 Participants
n=11 Participants • Participants were identified as white ethnocultural background or other.
|
11 Participants
n=11 Participants • Participants were identified as white ethnocultural background or other.
|
34 Participants
n=22 Participants • Participants were identified as white ethnocultural background or other.
|
38 Participants
n=255 Participants • Participants were identified as white ethnocultural background or other.
|
96 Participants
n=83 Participants • Participants were identified as white ethnocultural background or other.
|
|
Married or cohabiting
|
33 Participants
n=11 Participants
|
34 Participants
n=11 Participants
|
114 Participants
n=22 Participants
|
115 Participants
n=255 Participants
|
296 Participants
n=83 Participants
|
|
Employed Full Time
|
14 Participants
n=11 Participants
|
10 Participants
n=11 Participants
|
46 Participants
n=22 Participants
|
47 Participants
n=255 Participants
|
117 Participants
n=83 Participants
|
|
Current Smoker
|
1 Participants
n=11 Participants
|
1 Participants
n=11 Participants
|
2 Participants
n=22 Participants
|
3 Participants
n=255 Participants
|
7 Participants
n=83 Participants
|
|
Body Mass Index
|
27.0 kg/m^2
STANDARD_DEVIATION 5.1 • n=11 Participants
|
28.9 kg/m^2
STANDARD_DEVIATION 5.7 • n=11 Participants
|
29.0 kg/m^2
STANDARD_DEVIATION 4.8 • n=22 Participants
|
28.3 kg/m^2
STANDARD_DEVIATION 4.8 • n=255 Participants
|
28.44 kg/m^2
STANDARD_DEVIATION 5.04 • n=83 Participants
|
|
History of hypertension
|
36 Participants
n=11 Participants
|
47 Participants
n=11 Participants
|
94 Participants
n=22 Participants
|
83 Participants
n=255 Participants
|
260 Participants
n=83 Participants
|
|
History of dyslipidemia
|
33 Participants
n=11 Participants
|
48 Participants
n=11 Participants
|
99 Participants
n=22 Participants
|
99 Participants
n=255 Participants
|
279 Participants
n=83 Participants
|
|
History of diabetes mellitus
|
13 Participants
n=11 Participants
|
14 Participants
n=11 Participants
|
28 Participants
n=22 Participants
|
29 Participants
n=255 Participants
|
84 Participants
n=83 Participants
|
|
Prior cardiac history
|
7 Participants
n=11 Participants
|
5 Participants
n=11 Participants
|
15 Participants
n=22 Participants
|
24 Participants
n=255 Participants
|
51 Participants
n=83 Participants
|
|
History of peripheral vascular disease
|
2 Participants
n=11 Participants
|
2 Participants
n=11 Participants
|
4 Participants
n=22 Participants
|
1 Participants
n=255 Participants
|
9 Participants
n=83 Participants
|
|
History of heart failure
|
0 Participants
n=11 Participants
|
1 Participants
n=11 Participants
|
1 Participants
n=22 Participants
|
2 Participants
n=255 Participants
|
4 Participants
n=83 Participants
|
|
History of chronic kidney disease
|
1 Participants
n=11 Participants
|
0 Participants
n=11 Participants
|
4 Participants
n=22 Participants
|
4 Participants
n=255 Participants
|
9 Participants
n=83 Participants
|
|
Left ventricular ejection fraction
|
57.5 Percetange
STANDARD_DEVIATION 9.0 • n=11 Participants
|
59.8 Percetange
STANDARD_DEVIATION 7.3 • n=11 Participants
|
51.8 Percetange
STANDARD_DEVIATION 11.7 • n=22 Participants
|
54.3 Percetange
STANDARD_DEVIATION 11.2 • n=255 Participants
|
54.73 Percetange
STANDARD_DEVIATION 10.96 • n=83 Participants
|
|
Indication for Cardiac Rehab
Coronary artery bypass grafting
|
12 Participants
n=11 Participants
|
17 Participants
n=11 Participants
|
48 Participants
n=22 Participants
|
39 Participants
n=255 Participants
|
116 Participants
n=83 Participants
|
|
Indication for Cardiac Rehab
Percutaneous coronary intervention
|
43 Participants
n=11 Participants
|
38 Participants
n=11 Participants
|
102 Participants
n=22 Participants
|
100 Participants
n=255 Participants
|
283 Participants
n=83 Participants
|
|
Indication for Cardiac Rehab
Myocardial Infarction
|
36 Participants
n=11 Participants
|
30 Participants
n=11 Participants
|
78 Participants
n=22 Participants
|
71 Participants
n=255 Participants
|
215 Participants
n=83 Participants
|
|
Indication for Cardiac Rehab
Angina
|
6 Participants
n=11 Participants
|
10 Participants
n=11 Participants
|
10 Participants
n=22 Participants
|
13 Participants
n=255 Participants
|
39 Participants
n=83 Participants
|
|
Medication Use
Angiotension-converting enzyme inhibitor
|
33 Participants
n=11 Participants
|
33 Participants
n=11 Participants
|
92 Participants
n=22 Participants
|
83 Participants
n=255 Participants
|
241 Participants
n=83 Participants
|
|
Medication Use
Angiotension receptor blocker
|
14 Participants
n=11 Participants
|
18 Participants
n=11 Participants
|
13 Participants
n=22 Participants
|
15 Participants
n=255 Participants
|
60 Participants
n=83 Participants
|
|
Medication Use
Beta-blocker
|
49 Participants
n=11 Participants
|
54 Participants
n=11 Participants
|
121 Participants
n=22 Participants
|
121 Participants
n=255 Participants
|
345 Participants
n=83 Participants
|
|
Medication Use
Calcium channel blocker
|
13 Participants
n=11 Participants
|
11 Participants
n=11 Participants
|
19 Participants
n=22 Participants
|
24 Participants
n=255 Participants
|
67 Participants
n=83 Participants
|
|
Medication Use
Diuretic
|
7 Participants
n=11 Participants
|
10 Participants
n=11 Participants
|
17 Participants
n=22 Participants
|
9 Participants
n=255 Participants
|
43 Participants
n=83 Participants
|
|
Medication Use
Diabetes medication
|
6 Participants
n=11 Participants
|
11 Participants
n=11 Participants
|
28 Participants
n=22 Participants
|
21 Participants
n=255 Participants
|
66 Participants
n=83 Participants
|
|
Medication Use
Nitrates
|
24 Participants
n=11 Participants
|
32 Participants
n=11 Participants
|
63 Participants
n=22 Participants
|
55 Participants
n=255 Participants
|
174 Participants
n=83 Participants
|
|
Medication Use
Aspirin
|
60 Participants
n=11 Participants
|
61 Participants
n=11 Participants
|
151 Participants
n=22 Participants
|
145 Participants
n=255 Participants
|
417 Participants
n=83 Participants
|
|
Medication Use
Other anti-platlet medication
|
29 Participants
n=11 Participants
|
25 Participants
n=11 Participants
|
65 Participants
n=22 Participants
|
60 Participants
n=255 Participants
|
179 Participants
n=83 Participants
|
|
Medication Use
Statin
|
60 Participants
n=11 Participants
|
61 Participants
n=11 Participants
|
15 Participants
n=22 Participants
|
15 Participants
n=255 Participants
|
151 Participants
n=83 Participants
|
PRIMARY outcome
Timeframe: Baseline to 52 weeksPhysical activity will be measured directly by having participants wear the Actigraph GT3X accelerometer (Actigraph, Pensacola, Florida) over the right hip for a 9-day recording period, excluding periods when they are sleeping, swimming, or bathing. The activity monitor provides measurements including activity counts, energy expenditure, and step counts, in addition to activity intensity levels. Participants will be considered to be maintaining exercise at guideline recommended levels if they undertake ≥ 30 minutes of moderate and/or vigorous intensity physical activity on ≥ five days. The results report the average minutes of exercise recorded across the full 9 days wearing the accelerometer.
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity
at 52 weeks
|
216.9 Minutes of exercise
Standard Deviation 179.8
|
282.9 Minutes of exercise
Standard Deviation 206.9
|
284.8 Minutes of exercise
Standard Deviation 202.3
|
248.1 Minutes of exercise
Standard Deviation 160.6
|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity
Post-cardiac rehab (Baseline)
|
238.6 Minutes of exercise
Standard Deviation 176.1
|
314.1 Minutes of exercise
Standard Deviation 195.9
|
331.0 Minutes of exercise
Standard Deviation 207.4
|
272.9 Minutes of exercise
Standard Deviation 154.7
|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity
at 26 weeks
|
240.2 Minutes of exercise
Standard Deviation 189.0
|
316.8 Minutes of exercise
Standard Deviation 193.1
|
294.9 Minutes of exercise
Standard Deviation 208.7
|
274.6 Minutes of exercise
Standard Deviation 200.0
|
PRIMARY outcome
Timeframe: Baseline to 52 weeksPhysical activity will be measured directly by having participants wear the Actigraph GT3X accelerometer (Actigraph, Pensacola, Florida) over the right hip for a 9-day recording period, excluding periods when they are sleeping, swimming, or bathing. The activity monitor provides measurements including activity counts, energy expenditure, and step counts, in addition to activity intensity levels. Participants will be considered to be maintaining exercise at guideline recommended levels if they undertake ≥ 30 minutes of moderate and/or vigorous intensity physical activity on ≥ five days. Outcome measure 2 reports the average number of minutes recorded over the full 9 days of wearing the accelerometer, but only when the exercise events last for at least 10 minutes. This differs from Primary Outcome 1 because Primary Outcome 1 is an average of all bouts of exercise regardless of sustained time.
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity (>/= 10min Sessions)
Post-cardiac rehab (Baseline)
|
130.3 Minutes of exercise
Standard Deviation 116.9
|
178.7 Minutes of exercise
Standard Deviation 150.1
|
187.6 Minutes of exercise
Standard Deviation 137.4
|
156.5 Minutes of exercise
Standard Deviation 143.4
|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity (>/= 10min Sessions)
at 26 weeks
|
109.0 Minutes of exercise
Standard Deviation 116.2
|
175.7 Minutes of exercise
Standard Deviation 155.6
|
152.2 Minutes of exercise
Standard Deviation 146.5
|
163.2 Minutes of exercise
Standard Deviation 185.4
|
|
9-day Accelerometer-measured Physical Activity of Moderate and Vigorous Intensity (>/= 10min Sessions)
at 52 weeks
|
111.8 Minutes of exercise
Standard Deviation 113.1
|
149.3 Minutes of exercise
Standard Deviation 149.3
|
152.8 Minutes of exercise
Standard Deviation 148.9
|
150.0 Minutes of exercise
Standard Deviation 136.3
|
SECONDARY outcome
Timeframe: Baseline and 52 weeksPopulation: The number of participants in each group is lower than the total number analyzed because this test was completed by a subset of individuals only.
A random sub-sample of participants will complete a symptom limited graded exercise test with electrocardiographic monitoring using a ramp protocol on a treadmill at baseline and at 52 weeks. Exercise tolerance will also be assessed using the Duke Activity Status Index (DASI), a self-administered questionnaire that measures a patient's functional capacity and is used as an estimate of an individual's peak oxygen uptake
Outcome measures
| Measure |
Usual Care - Female Participants
n=30 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=59 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=63 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=28 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
Symptom Limited Graded Exercise Test With Electrocardiographic Monitoring Using a Ramp Protocol on a Treadmill
post-cardiac rehab (Baseline)
|
20.77 mL O2/kg/min
Standard Deviation 4.19
|
26.16 mL O2/kg/min
Standard Deviation 6.32
|
26.49 mL O2/kg/min
Standard Deviation 7.26
|
22.05 mL O2/kg/min
Standard Deviation 5.10
|
|
Symptom Limited Graded Exercise Test With Electrocardiographic Monitoring Using a Ramp Protocol on a Treadmill
at 52 weeks
|
20.32 mL O2/kg/min
Standard Deviation 5.05
|
25.67 mL O2/kg/min
Standard Deviation 6.26
|
27.41 mL O2/kg/min
Standard Deviation 8.19
|
23.45 mL O2/kg/min
Standard Deviation 4.88
|
SECONDARY outcome
Timeframe: Baseline to 52 weeksThe EQ-5D is the current gold standard measure of generic quality of life, has been used in numerous studies and has been validated in many languages. The EQ-5D consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale. The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The Visual analogue scale ranges from 0-100 with 0 rated as the worst health, and 100 being the best health.
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=157 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
Quality of Life Measured by the the EuroQoL 5D Visual Analogue Scale
Baseline
|
79.1 Score on a scale
Standard Deviation 12.8
|
75.6 Score on a scale
Standard Deviation 14.6
|
79.1 Score on a scale
Standard Deviation 12.4
|
75.6 Score on a scale
Standard Deviation 13.4
|
|
Quality of Life Measured by the the EuroQoL 5D Visual Analogue Scale
26 week
|
78.1 Score on a scale
Standard Deviation 11.6
|
76.7 Score on a scale
Standard Deviation 14.7
|
77.8 Score on a scale
Standard Deviation 12.7
|
77.8 Score on a scale
Standard Deviation 15.1
|
|
Quality of Life Measured by the the EuroQoL 5D Visual Analogue Scale
52 week
|
78.9 Score on a scale
Standard Deviation 10.3
|
79.5 Score on a scale
Standard Deviation 12.0
|
80.2 Score on a scale
Standard Deviation 11.7
|
77.2 Score on a scale
Standard Deviation 14.7
|
SECONDARY outcome
Timeframe: 52 weeksWaist circumference is measured using a non-stretchable standard tape measure.
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
Cardiovascular Risk Factors Measured by Waist Circumference
at 26 weeks
|
95.4 centimeters
Standard Deviation 14.6
|
103.9 centimeters
Standard Deviation 11.2
|
101.6 centimeters
Standard Deviation 12.8
|
95.5 centimeters
Standard Deviation 18.5
|
|
Cardiovascular Risk Factors Measured by Waist Circumference
at 52 weeks
|
95.3 centimeters
Standard Deviation 12.0
|
103.7 centimeters
Standard Deviation 12.4
|
102.0 centimeters
Standard Deviation 14.2
|
91.7 centimeters
Standard Deviation 13.6
|
|
Cardiovascular Risk Factors Measured by Waist Circumference
Baseline
|
94.7 centimeters
Standard Deviation 13.5
|
102.5 centimeters
Standard Deviation 12.0
|
100.0 centimeters
Standard Deviation 12.9
|
91.7 centimeters
Standard Deviation 13.1
|
SECONDARY outcome
Timeframe: 52 weeksSystolic blood pressure is measured in a seated position after a five-minute rest period using an automated, non-invasive blood pressure monitor (BPTru) that automatically performs six measurements. The results represent the average measurements of the six measurements taken.
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
Cardiovascular Risk Factors Measured by Systolic Blood Pressure.
at 52 weeks
|
127.2 mmHg
Standard Deviation 15.2
|
125.4 mmHg
Standard Deviation 14.8
|
126.2 mmHg
Standard Deviation 15.2
|
120.7 mmHg
Standard Deviation 15.0
|
|
Cardiovascular Risk Factors Measured by Systolic Blood Pressure.
Baseline
|
121.8 mmHg
Standard Deviation 17.1
|
120.4 mmHg
Standard Deviation 15.8
|
120.1 mmHg
Standard Deviation 17.1
|
117.5 mmHg
Standard Deviation 16.3
|
|
Cardiovascular Risk Factors Measured by Systolic Blood Pressure.
at 26 weeks
|
127.5 mmHg
Standard Deviation 17.7
|
124.7 mmHg
Standard Deviation 19.0
|
126.2 mmHg
Standard Deviation 17.7
|
124.0 mmHg
Standard Deviation 17.0
|
SECONDARY outcome
Timeframe: 52 weeksHeight and weight is measured for the determination of body mass index (BMI).
Outcome measures
| Measure |
Usual Care - Female Participants
n=67 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Male Participants.
n=158 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
Usual Care - Male Participants
n=156 Participants
Participants were provided with an updated exercise prescription based on their exit stress tests, which were also shared with their primary care providers.
|
Exercise Facilitator Intervention - Female Participants
n=68 Participants
EFI participants received a face-to-face introductory session, 5 small-group counseling teleconferences, and 3 personal calls from a trained facilitator over 50 weeks.
|
|---|---|---|---|---|
|
Cardiovascular Risk Factors Measured by Body Mass Index
Baseline
|
28.94 kg/m^2
Standard Deviation 5.67
|
28.93 kg/m^2
Standard Deviation 4.37
|
28.27 kg/m^2
Standard Deviation 4.77
|
27.02 kg/m^2
Standard Deviation 5.59
|
|
Cardiovascular Risk Factors Measured by Body Mass Index
at 26 weeks
|
29.14 kg/m^2
Standard Deviation 5.28
|
28.94 kg/m^2
Standard Deviation 4.84
|
28.90 kg/m^2
Standard Deviation 5.15
|
27.35 kg/m^2
Standard Deviation 6.26
|
|
Cardiovascular Risk Factors Measured by Body Mass Index
at 52 weeks
|
28.98 kg/m^2
Standard Deviation 5.02
|
29.30 kg/m^2
Standard Deviation 4.48
|
29.04 kg/m^2
Standard Deviation 5.39
|
26.83 kg/m^2
Standard Deviation 5.73
|
Adverse Events
Exercise Facilitator Intervention - Female Participants
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Usual Care - Female Participants
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Exercise Facilitator Intervention - Male Participants.
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Usual Care - Male Participants
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place